- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: BAY 1143572 | BAY-1143572 | BAY1143572
Compound class: Synthetic organic
Comment: Atuveciclib (BAY 1143572) is an orally active, selective CDK9 inhibitor . It was the first inhibitor of its class to enter clinical development. The potency of atuveciclib is diminished at physiological ATP concentration compared to at the low ATP concentrations used in in vitro assays, Therefore, it was used as the starting point for the development of a more optimised inhibitor enitociclib .
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Lücking U, Kosemund D, Böhnke N, Lienau P, Siemeister G, Denner K, Bohlmann R, Briem H, Terebesi I, Bömer U et al.. (2021)
Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.
J Med Chem, 64 (15): 11651-11674. [PMID:34264057]
2. Lücking U, Scholz A, Lienau P, Siemeister G, Kosemund D, Bohlmann R, Briem H, Terebesi I, Meyer K, Prelle K et al.. (2017)
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer.
ChemMedChem, 12 (21): 1776-1793. [PMID:28961375]